Web based Drug Database (1.07 Linux)

MELOXICAM [RECTUM]

Names
Common Name	MELOXICAM [RECTUM]
Other Name	MELOXICAM [RECTUM]
Pharmacological Group	NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
Chemical Name	4-Hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide
Chemical Group

Attributes

Indications	Contraindications	Prescriber Cautions	Patient Cautions
Toxicity	Side Effects	Liver Disease	Renal Failure
Pregnancy	Lactation	Pharmacological Actions	Diagnostic Procedures
Drugs	Interactions

Indications

Gout
Ankylosing spondylitis

Contraindications

Asthma
Peptic ulcer
Analgesic allergy
Disorders of porphyrin metabolism
Chronic asthmatic bronchitis
Peptic ulcer of oesophagus
Gastric ulcer
Duodenal ulcer
Peptic ulcer - (PU) site unspecified
Gastrojejunal ulcer
Gastritis and duodenitis
Rectal haemorrhage
Proctitis
Angioneurotic oedema
Adverse reaction to antirheumatics
Airways obstruction reversible
Non-steroidal anti-inflammatory drugs contraindicated

Prescriber Cautions

Consult current official advice regarding MELOXICAM [RECTUM]
Not recommended for children
Regular renal function tests advised during prolonged treatment with MELOXICAM [RECTUM]
Regular monitoring of patient for signs of gastrointestinal bleeding during prolonged treatment with MELOXICAM [RECTUM]

Patient Cautions

See information on products containing MELOXICAM [RECTUM] for specific advice for patients

Toxicity

- None Listed -

Side Effects

Abdominal pain - Very Common
Constipation - Very Common
Diarrhoea - Very Common
Dyspepsia - Very Common
Excessive flatulence - Very Common
Nausea - Very Common
Vomiting - Very Common
Headache - Common
Acute gastritis - Uncommon
ALT/SGPT level abnormal - Uncommon
Anaemia - Uncommon
Angioneurotic oedema - Uncommon
AST/SGOT level raised - Uncommon
Blood pressure raised - Uncommon
Dizziness - Uncommon
Excessive eructation - Uncommon
Fluid retention - Uncommon
Flushing - Uncommon
Hyperkalaemia - Uncommon
Hyperosmolality/hypernatraemia - Uncommon
Itching - Uncommon
Liver function tests abnormal - Uncommon
Oedema - Uncommon
Painless rectal bleeding - Uncommon
Rash - Uncommon
Serum bilirubin raised - Uncommon
Somnolence - Uncommon
Sore mouth - Uncommon
Acute conjunctivitis - Rare
Blurred Vision - Rare
Bronchospasm - Rare
Enteritis/colitis - Rare
Leucopenia - Rare
Mood swings - Rare
Nightmares - Rare
Palpitations - Rare
Peptic ulcer symptoms - Rare
Stevens-Johnson syndrome - Rare
Thrombocytopenia - Rare
Tinnitus - Rare
Toxic epidermal necrolysis - Rare
Ulcerative oesophagitis - Rare
Acute hepatitis - Very Rare
Acute renal failure - Very Rare
Agranulocytosis - Very Rare
Bullous eruption - Very Rare
Erythema multiforme - Very Rare
Perforation of intestine - Very Rare
Anaphylactic shock
Confusion
Congestive heart failure
Disorientation
Photosensitiveness

Liver Disease

Avoid MELOXICAM [RECTUM] in severe liver disease
MELOXICAM [RECTUM] causes sodium and water retention in liver disease
MELOXICAM [RECTUM] - increased risk of gastrointestinal bleeding in liver disease

Renal Failure

Avoid MELOXICAM [RECTUM] if possible in mild renal failure
Manufacturer advises reduce dose of MELOXICAM [RECTUM] in renal failure
MELOXICAM [RECTUM] - reduces renal function in renal failure
MELOXICAM [RECTUM] - sodium and water retention in renal failure

Pregnancy

With regular doses of MELOXICAM [RECTUM] - increased risk of closure of fetal ductus arteriosus in utero & possible persistent pulmonary hypertension of the newborn
Delayed onset & increased duration of labour with increased blood loss
Avoid MELOXICAM [RECTUM] in the 1st TRIMESTER of pregnancy
Avoid MELOXICAM [RECTUM] in the 3rd TRIMESTER of pregnancy
Manufacturer advises toxicity of MELOXICAM [RECTUM] in pregnancy in animal studies

Lactation

Manufacturer advises avoid MELOXICAM [RECTUM] in breast feeding

Pharmacological Actions

ANALGESIC effect
ANTIINFLAMMATORY effect
ANTIPYRETIC effect
CYCLOOXYGENASE INHIBITOR effect
Preferential CYCLOOXYGENASE-2 INHIBITOR effect

Diagnostic Procedures

- None Listed -

Drugs containing MELOXICAM [RECTUM]

MELOXICAM 15mg suppositories
MOBIC 15mg suppositories
MELOXICAM 7.5mg suppositories
MOBIC 7.5mg suppositories

Interacting Ingredients

ACECLOFENAC
Likely interaction of ACECLOFENAC increasing the GASTRIC IRRITANT effect of MELOXICAM [RECTUM]. Moderate risk. May need to avoid combination
ACEMETACIN
Likely interaction of MELOXICAM [RECTUM] increasing the GASTRIC IRRITANT effect of ACEMETACIN. Moderate risk. May need to avoid combination
ALOXIPRIN
Likely interaction of MELOXICAM [RECTUM] increasing the GASTRIC IRRITANT effect of ALOXIPRIN. Moderate risk. May need to avoid combination
AMINOPHYLLINE
Infrequent reports of MELOXICAM [RECTUM] reducing the BRONCHODILATOR effect of AMINOPHYLLINE. Moderate risk. Avoid
ASPIRIN
Likely interaction of MELOXICAM [RECTUM] increasing the GASTRIC IRRITANT effect of ASPIRIN. Moderate risk. May need to avoid combination
ASPIRIN [RECTUM]
Likely interaction of MELOXICAM [RECTUM] increasing the GASTRIC IRRITANT effect of ASPIRIN [RECTUM]. Moderate risk. May need to avoid combination
AZAPROPAZONE
Likely interaction of MELOXICAM [RECTUM] increasing the GASTRIC IRRITANT effect of AZAPROPAZONE. Moderate risk. May need to avoid combination
BAMBUTEROL HYDROCHLORIDE
Infrequent reports of MELOXICAM [RECTUM] reducing the BRONCHODILATOR effect of BAMBUTEROL HYDROCHLORIDE. Moderate risk. Avoid
BECLOMETASONE [INHALED]
Infrequent reports of MELOXICAM [RECTUM] reducing the BRONCHODILATOR effect of BECLOMETASONE [INHALED]. Moderate risk. Avoid
BENORILATE
Likely interaction of BENORILATE increasing the GASTRIC IRRITANT effect of MELOXICAM [RECTUM]. Moderate risk. May need to avoid combination
BETAMETHASONE
Likely interaction of BETAMETHASONE increasing the GASTRIC IRRITANT effect of MELOXICAM [RECTUM]. Moderate risk. Monitor
BETAMETHASONE [INHALED]
Infrequent reports of MELOXICAM [RECTUM] reducing the BRONCHODILATOR effect of BETAMETHASONE [INHALED]. Moderate risk. Avoid
BISMUTH CHELATE
Likely interaction of MELOXICAM [RECTUM] reducing the ULCER HEALING effect of BISMUTH CHELATE. Moderate risk. Avoid
BUDESONIDE [GASTROINTESTINAL]
Likely interaction of BUDESONIDE [GASTROINTESTINAL] increasing the GASTRIC IRRITANT effect of MELOXICAM [RECTUM]. Moderate risk. Monitor
BUDESONIDE [INHALED]
Infrequent reports of MELOXICAM [RECTUM] reducing the BRONCHODILATOR effect of BUDESONIDE [INHALED]. Moderate risk. Avoid
BUFYLLINE
Infrequent reports of MELOXICAM [RECTUM] reducing the BRONCHODILATOR effect of BUFYLLINE. Moderate risk. Avoid
CANDESARTAN CILEXETIL
Likely interaction of MELOXICAM [RECTUM] increasing the NEPHROTOXICITY of CANDESARTAN CILEXETIL. Potential risk. Monitor
CARBENOXOLONE
Likely interaction of MELOXICAM [RECTUM] reducing the ULCER HEALING effect of CARBENOXOLONE. Moderate risk. Avoid
CHOLINE MAGNESIUM TRISALICYLATE
Likely interaction of CHOLINE MAGNESIUM TRISALICYLATE increasing the GASTRIC IRRITANT effect of MELOXICAM [RECTUM]. Moderate risk. May need to avoid combination
CHOLINE THEOPHYLLINATE
Infrequent reports of MELOXICAM [RECTUM] reducing the BRONCHODILATOR effect of CHOLINE THEOPHYLLINATE. Moderate risk. Avoid
CIMETIDINE
Likely interaction of MELOXICAM [RECTUM] reducing the ULCER HEALING effect of CIMETIDINE. Moderate risk. Avoid
CLOPIDOGREL
Theoretical potential for MELOXICAM [RECTUM] increasing the PLATELET ANTAGONIST effect of CLOPIDOGREL. Moderate risk. May need to avoid combination
COLESTYRAMINE
Likely interaction of COLESTYRAMINE reducing the SERUM LEVEL of MELOXICAM [RECTUM]. Moderate risk. Monitor
CORTISONE ACETATE
Likely interaction of CORTISONE ACETATE increasing the GASTRIC IRRITANT effect of MELOXICAM [RECTUM]. Moderate risk. Monitor
CROMOGLICATE [INHALED]
Infrequent reports of MELOXICAM [RECTUM] reducing the BRONCHODILATOR effect of CROMOGLICATE [INHALED]. Moderate risk. Avoid
DANAPAROID SODIUM
Theoretical potential for MELOXICAM [RECTUM] increasing the ANTICOAGULANT effect of DANAPAROID SODIUM. Moderate risk. May need to avoid combination
DEGLYCYRRHIZINISED LIQUORICE
Likely interaction of MELOXICAM [RECTUM] reducing the ULCER HEALING effect of DEGLYCYRRHIZINISED LIQUORICE. Moderate risk. Avoid
DEXAMETHASONE [ORAL]
Likely interaction of DEXAMETHASONE [ORAL] increasing the GASTRIC IRRITANT effect of MELOXICAM [RECTUM]. Moderate risk. Monitor
DEXAMETHASONE [PARENTERAL]
Likely interaction of DEXAMETHASONE [PARENTERAL] increasing the GASTRIC IRRITANT effect of MELOXICAM [RECTUM]. Moderate risk. Monitor
DEXIBUPROFEN
Likely interaction of MELOXICAM [RECTUM] increasing the GASTRIC IRRITANT effect of DEXIBUPROFEN. Moderate risk. May need to avoid combination
DEXKETOPROFEN
Likely interaction of DEXKETOPROFEN increasing the GASTRIC IRRITANT effect of MELOXICAM [RECTUM]. Moderate risk. May need to avoid combination
DICLOFENAC POTASSIUM
Likely interaction of MELOXICAM [RECTUM] increasing the GASTRIC IRRITANT effect of DICLOFENAC POTASSIUM. Moderate risk. May need to avoid combination
DICLOFENAC SODIUM [ORAL]
Likely interaction of MELOXICAM [RECTUM] increasing the GASTRIC IRRITANT effect of DICLOFENAC SODIUM [ORAL]. Moderate risk. May need to avoid combination
DICLOFENAC SODIUM [PARENTERAL]
Likely interaction of MELOXICAM [RECTUM] increasing the GASTRIC IRRITANT effect of DICLOFENAC SODIUM [PARENTERAL]. Moderate risk. May need to avoid combination
DICLOFENAC SODIUM [RECTUM]
Likely interaction of MELOXICAM [RECTUM] increasing the GASTRIC IRRITANT effect of DICLOFENAC SODIUM [RECTUM]. Moderate risk. May need to avoid combination
DIFLUNISAL
Likely interaction of DIFLUNISAL increasing the GASTRIC IRRITANT effect of MELOXICAM [RECTUM]. Moderate risk. May need to avoid combination
DIPROPHYLLINE
Infrequent reports of MELOXICAM [RECTUM] reducing the BRONCHODILATOR effect of DIPROPHYLLINE. Moderate risk. Avoid
ENOXAPARIN
Likely interaction of MELOXICAM [RECTUM] increasing the ANTICOAGULANT effect of ENOXAPARIN. Moderate risk. May need to avoid combination
EPHEDRINE HYDROCHLORIDE
Infrequent reports of MELOXICAM [RECTUM] reducing the BRONCHODILATOR effect of EPHEDRINE HYDROCHLORIDE. Moderate risk. Avoid
EPROSARTAN
Likely interaction of MELOXICAM [RECTUM] increasing the NEPHROTOXICITY of EPROSARTAN. Potential risk. Monitor
ESOMEPRAZOLE
Likely interaction of MELOXICAM [RECTUM] reducing the ULCER HEALING effect of ESOMEPRAZOLE. Moderate risk. Avoid
ETODOLAC
Likely interaction of MELOXICAM [RECTUM] increasing the GASTRIC IRRITANT effect of ETODOLAC. Moderate risk. May need to avoid combination
FAMOTIDINE
Likely interaction of MELOXICAM [RECTUM] reducing the ULCER HEALING effect of FAMOTIDINE. Moderate risk. Avoid
FENBUFEN
Likely interaction of FENBUFEN increasing the GASTRIC IRRITANT effect of MELOXICAM [RECTUM]. Moderate risk. May need to avoid combination
FENOPROFEN
Likely interaction of MELOXICAM [RECTUM] increasing the GASTRIC IRRITANT effect of FENOPROFEN. Moderate risk. May need to avoid combination
FENOTEROL HYDROBROMIDE
Infrequent reports of MELOXICAM [RECTUM] reducing the BRONCHODILATOR effect of FENOTEROL HYDROBROMIDE. Moderate risk. Avoid
FLUDROCORTISONE ACETATE
Likely interaction of FLUDROCORTISONE ACETATE increasing the GASTRIC IRRITANT effect of MELOXICAM [RECTUM]. Moderate risk. Monitor
FLURBIPROFEN
Likely interaction of MELOXICAM [RECTUM] increasing the GASTRIC IRRITANT effect of FLURBIPROFEN. Moderate risk. May need to avoid combination
FLURBIPROFEN [RECTUM]
Likely interaction of MELOXICAM [RECTUM] increasing the GASTRIC IRRITANT effect of FLURBIPROFEN [RECTUM]. Moderate risk. May need to avoid combination
FLUTICASONE [INHALED]
Infrequent reports of MELOXICAM [RECTUM] reducing the BRONCHODILATOR effect of FLUTICASONE [INHALED]. Moderate risk. Avoid
FONDAPARINUX SODIUM
Likely interaction of MELOXICAM [RECTUM] increasing the ANTICOAGULANT effect of FONDAPARINUX SODIUM. Moderate risk. May need to avoid combination
FORMOTEROL
Infrequent reports of MELOXICAM [RECTUM] reducing the BRONCHODILATOR effect of FORMOTEROL. Moderate risk. Avoid
HYDROCORTISONE
Likely interaction of HYDROCORTISONE increasing the GASTRIC IRRITANT effect of MELOXICAM [RECTUM]. Moderate risk. Monitor
HYDROCORTISONE SODIUM PHOSPHATE
Likely interaction of HYDROCORTISONE SODIUM PHOSPHATE increasing the GASTRIC IRRITANT effect of MELOXICAM [RECTUM]. Moderate risk. Monitor
HYDROCORTISONE SODIUM SUCCINATE
Likely interaction of HYDROCORTISONE SODIUM SUCCINATE increasing the GASTRIC IRRITANT effect of MELOXICAM [RECTUM]. Moderate risk. Monitor
IBUPROFEN
Likely interaction of MELOXICAM [RECTUM] increasing the GASTRIC IRRITANT effect of IBUPROFEN. Moderate risk. May need to avoid combination
IBUPROFEN LYSINE
Likely interaction of MELOXICAM [RECTUM] increasing the GASTRIC IRRITANT effect of IBUPROFEN LYSINE. Moderate risk. May need to avoid combination
INDACATEROL
Infrequent reports of MELOXICAM [RECTUM] reducing the BRONCHODILATOR effect of INDACATEROL. Moderate risk. Avoid
INDOMETACIN
Likely interaction of INDOMETACIN increasing the GASTRIC IRRITANT effect of MELOXICAM [RECTUM]. Moderate risk. May need to avoid combination
INDOMETACIN [RECTUM]
Likely interaction of INDOMETACIN [RECTUM] increasing the GASTRIC IRRITANT effect of MELOXICAM [RECTUM]. Moderate risk. May need to avoid combination
IRBESARTAN
Likely interaction of MELOXICAM [RECTUM] increasing the NEPHROTOXICITY of IRBESARTAN. Potential risk. Monitor
ISOETARINE HYDROCHLORIDE
Infrequent reports of MELOXICAM [RECTUM] reducing the BRONCHODILATOR effect of ISOETARINE HYDROCHLORIDE. Moderate risk. Avoid
ISOPRENALINE HYDROCHLORIDE
Infrequent reports of MELOXICAM [RECTUM] reducing the BRONCHODILATOR effect of ISOPRENALINE HYDROCHLORIDE. Moderate risk. Avoid
ISOPRENALINE SULPHATE
Infrequent reports of MELOXICAM [RECTUM] reducing the BRONCHODILATOR effect of ISOPRENALINE SULPHATE. Moderate risk. Avoid
KETOPROFEN
Likely interaction of KETOPROFEN increasing the GASTRIC IRRITANT effect of MELOXICAM [RECTUM]. Moderate risk. May need to avoid combination
KETOPROFEN [RECTUM]
Likely interaction of KETOPROFEN [RECTUM] increasing the GASTRIC IRRITANT effect of MELOXICAM [RECTUM]. Moderate risk. May need to avoid combination
KETOROLAC TROMETAMOL
Likely interaction of MELOXICAM [RECTUM] increasing the PLATELET ANTAGONIST effect of KETOROLAC TROMETAMOL. High risk. Avoid
KETOTIFEN
Infrequent reports of MELOXICAM [RECTUM] reducing the BRONCHODILATOR effect of KETOTIFEN. Moderate risk. Avoid
LANSOPRAZOLE
Likely interaction of MELOXICAM [RECTUM] reducing the ULCER HEALING effect of LANSOPRAZOLE. Moderate risk. Avoid
LITHIUM CARBONATE
Theoretical potential for MELOXICAM [RECTUM] increasing the SERUM LEVEL of LITHIUM CARBONATE. Potential risk. Monitor
LITHIUM CHLORIDE [PARENTERAL]
Theoretical potential for MELOXICAM [RECTUM] increasing the SERUM LEVEL of LITHIUM CHLORIDE [PARENTERAL]. Potential risk. Monitor
LITHIUM CITRATE
Theoretical potential for MELOXICAM [RECTUM] increasing the SERUM LEVEL of LITHIUM CITRATE. Potential risk. Monitor
LOSARTAN POTASSIUM
Likely interaction of MELOXICAM [RECTUM] increasing the NEPHROTOXICITY of LOSARTAN POTASSIUM. Potential risk. Monitor
LYSINE ASPIRIN
Likely interaction of MELOXICAM [RECTUM] increasing the GASTRIC IRRITANT effect of LYSINE ASPIRIN. Moderate risk. May need to avoid combination
MEFENAMIC ACID
Likely interaction of MELOXICAM [RECTUM] increasing the GASTRIC IRRITANT effect of MEFENAMIC ACID. Moderate risk. May need to avoid combination
MESALAZINE
Theoretical potential for MELOXICAM [RECTUM] increasing the NEPHROTOXICITY of MESALAZINE. Potential risk. May need to avoid combination
METHYLEPHEDRINE
Infrequent reports of MELOXICAM [RECTUM] reducing the BRONCHODILATOR effect of METHYLEPHEDRINE. Moderate risk. Avoid
METHYLPREDNISOLONE
Likely interaction of METHYLPREDNISOLONE increasing the GASTRIC IRRITANT effect of MELOXICAM [RECTUM]. Moderate risk. Monitor
MIFEPRISTONE
Theoretical potential for MELOXICAM [RECTUM] increasing the PROSTANERGIC effect of MIFEPRISTONE. Potential risk. Avoid
MONTELUKAST
Infrequent reports of MELOXICAM [RECTUM] reducing the BRONCHODILATOR effect of MONTELUKAST. Moderate risk. Avoid
NABUMETONE
Likely interaction of NABUMETONE increasing the GASTRIC IRRITANT effect of MELOXICAM [RECTUM]. Moderate risk. May need to avoid combination
NAPROXEN
Likely interaction of NAPROXEN increasing the GASTRIC IRRITANT effect of MELOXICAM [RECTUM]. Moderate risk. May need to avoid combination
NAPROXEN SODIUM
Likely interaction of MELOXICAM [RECTUM] increasing the GASTRIC IRRITANT effect of NAPROXEN SODIUM. Moderate risk. May need to avoid combination
NAPROXEN [RECTUM]
Likely interaction of NAPROXEN [RECTUM] increasing the GASTRIC IRRITANT effect of MELOXICAM [RECTUM]. Moderate risk. May need to avoid combination
NEDOCROMIL SODIUM
Infrequent reports of MELOXICAM [RECTUM] reducing the BRONCHODILATOR effect of NEDOCROMIL SODIUM. Moderate risk. Avoid
NIZATIDINE
Likely interaction of MELOXICAM [RECTUM] reducing the ULCER HEALING effect of NIZATIDINE. Moderate risk. Avoid
OLMESARTAN MEDOXOMIL
Likely interaction of MELOXICAM [RECTUM] increasing the NEPHROTOXICITY of OLMESARTAN MEDOXOMIL. Potential risk. Monitor
OMEPRAZOLE [ORAL]
Likely interaction of MELOXICAM [RECTUM] reducing the ULCER HEALING effect of OMEPRAZOLE [ORAL]. Moderate risk. Avoid
OMEPRAZOLE [PARENTERAL]
Likely interaction of MELOXICAM [RECTUM] reducing the ULCER HEALING effect of OMEPRAZOLE [PARENTERAL]. Moderate risk. Avoid
ORCIPRENALINE
Infrequent reports of MELOXICAM [RECTUM] reducing the BRONCHODILATOR effect of ORCIPRENALINE. Moderate risk. Avoid
ORCIPRENALINE [INHALED]
Infrequent reports of MELOXICAM [RECTUM] reducing the BRONCHODILATOR effect of ORCIPRENALINE [INHALED]. Moderate risk. Avoid
PANTOPRAZOLE
Likely interaction of MELOXICAM [RECTUM] reducing the ULCER HEALING effect of PANTOPRAZOLE. Moderate risk. Avoid
PHENYLBUTAZONE
Likely interaction of PHENYLBUTAZONE increasing the GASTRIC IRRITANT effect of MELOXICAM [RECTUM]. Moderate risk. May need to avoid combination
PIRBUTEROL
Infrequent reports of MELOXICAM [RECTUM] reducing the BRONCHODILATOR effect of PIRBUTEROL. Moderate risk. Avoid
PIROXICAM
Likely interaction of MELOXICAM [RECTUM] increasing the GASTRIC IRRITANT effect of PIROXICAM. Moderate risk. May need to avoid combination
PIROXICAM [RECTUM]
Likely interaction of MELOXICAM [RECTUM] increasing the GASTRIC IRRITANT effect of PIROXICAM [RECTUM]. Moderate risk. May need to avoid combination
PIROXICAM-BETADEX
Likely interaction of PIROXICAM-BETADEX increasing the GASTRIC IRRITANT effect of MELOXICAM [RECTUM]. Moderate risk. May need to avoid combination
PREDNISOLONE
Likely interaction of PREDNISOLONE increasing the GASTRIC IRRITANT effect of MELOXICAM [RECTUM]. Moderate risk. Monitor
PREDNISOLONE ACETATE
Likely interaction of PREDNISOLONE ACETATE increasing the GASTRIC IRRITANT effect of MELOXICAM [RECTUM]. Moderate risk. Monitor
PREDNISOLONE SODIUM PHOSPHATE
Likely interaction of PREDNISOLONE SODIUM PHOSPHATE increasing the GASTRIC IRRITANT effect of MELOXICAM [RECTUM]. Moderate risk. Monitor
PREDNISONE
Likely interaction of PREDNISONE increasing the GASTRIC IRRITANT effect of MELOXICAM [RECTUM]. Moderate risk. Monitor
RABEPRAZOLE
Likely interaction of MELOXICAM [RECTUM] reducing the ULCER HEALING effect of RABEPRAZOLE. Moderate risk. Avoid
RANITIDINE
Likely interaction of MELOXICAM [RECTUM] reducing the ULCER HEALING effect of RANITIDINE. Moderate risk. Avoid
RANITIDINE BISMUTH CITRATE
Likely interaction of MELOXICAM [RECTUM] reducing the ULCER HEALING effect of RANITIDINE BISMUTH CITRATE. Moderate risk. Avoid
REPROTEROL HYDROCHLORIDE
Infrequent reports of MELOXICAM [RECTUM] reducing the BRONCHODILATOR effect of REPROTEROL HYDROCHLORIDE. Moderate risk. Avoid
RIMITEROL HYDROBROMIDE
Infrequent reports of MELOXICAM [RECTUM] reducing the BRONCHODILATOR effect of RIMITEROL HYDROBROMIDE. Moderate risk. Avoid
RITODRINE HYDROCHLORIDE
Infrequent reports of MELOXICAM [RECTUM] reducing the BRONCHODILATOR effect of RITODRINE HYDROCHLORIDE. Moderate risk. Avoid
SALBUTAMOL
Infrequent reports of MELOXICAM [RECTUM] reducing the BRONCHODILATOR effect of SALBUTAMOL. Moderate risk. Avoid
SALBUTAMOL [INHALED]
Infrequent reports of MELOXICAM [RECTUM] reducing the BRONCHODILATOR effect of SALBUTAMOL [INHALED]. Moderate risk. Avoid
SALICYLAMIDE
Likely interaction of SALICYLAMIDE increasing the GASTRIC IRRITANT effect of MELOXICAM [RECTUM]. Moderate risk. May need to avoid combination
SALIX
Likely interaction of SALIX increasing the GASTRIC IRRITANT effect of MELOXICAM [RECTUM]. Moderate risk. May need to avoid combination
SALMETEROL XINAFOATE
Infrequent reports of MELOXICAM [RECTUM] reducing the BRONCHODILATOR effect of SALMETEROL XINAFOATE. Moderate risk. Avoid
SALSALATE
Likely interaction of MELOXICAM [RECTUM] increasing the GASTRIC IRRITANT effect of SALSALATE. Moderate risk. May need to avoid combination
SODIUM SALICYLATE
Likely interaction of MELOXICAM [RECTUM] increasing the GASTRIC IRRITANT effect of SODIUM SALICYLATE. Moderate risk. May need to avoid combination
SUCRALFATE
Likely interaction of MELOXICAM [RECTUM] reducing the ULCER HEALING effect of SUCRALFATE. Moderate risk. Avoid
SULINDAC
Likely interaction of SULINDAC increasing the GASTRIC IRRITANT effect of MELOXICAM [RECTUM]. Moderate risk. May need to avoid combination
TELMISARTAN
Likely interaction of MELOXICAM [RECTUM] increasing the NEPHROTOXICITY of TELMISARTAN. Potential risk. Monitor
TENOXICAM
Likely interaction of TENOXICAM increasing the GASTRIC IRRITANT effect of MELOXICAM [RECTUM]. Moderate risk. May need to avoid combination
TERBUTALINE
Infrequent reports of MELOXICAM [RECTUM] reducing the BRONCHODILATOR effect of TERBUTALINE. Moderate risk. Avoid
TERBUTALINE [INHALED]
Infrequent reports of MELOXICAM [RECTUM] reducing the BRONCHODILATOR effect of TERBUTALINE [INHALED]. Moderate risk. Avoid
THEOPHYLLINE
Infrequent reports of MELOXICAM [RECTUM] reducing the BRONCHODILATOR effect of THEOPHYLLINE. Moderate risk. Avoid
TIAPROFENIC ACID
Likely interaction of TIAPROFENIC ACID increasing the GASTRIC IRRITANT effect of MELOXICAM [RECTUM]. Moderate risk. May need to avoid combination
TINZAPARIN SODIUM
Likely interaction of MELOXICAM [RECTUM] increasing the ANTICOAGULANT effect of TINZAPARIN SODIUM. Moderate risk. May need to avoid combination
TOLFENAMIC ACID
Likely interaction of TOLFENAMIC ACID increasing the GASTRIC IRRITANT effect of MELOXICAM [RECTUM]. Moderate risk. May need to avoid combination
TOLMETIN
Likely interaction of MELOXICAM [RECTUM] increasing the GASTRIC IRRITANT effect of TOLMETIN. Moderate risk. May need to avoid combination
TRIAMCINOLONE ACETONIDE
Likely interaction of TRIAMCINOLONE ACETONIDE increasing the GASTRIC IRRITANT effect of MELOXICAM [RECTUM]. Moderate risk. Monitor
TULOBUTEROL HYDROCHLORIDE
Infrequent reports of MELOXICAM [RECTUM] reducing the BRONCHODILATOR effect of TULOBUTEROL HYDROCHLORIDE. Moderate risk. Avoid
VALSARTAN
Likely interaction of MELOXICAM [RECTUM] increasing the NEPHROTOXICITY of VALSARTAN. Potential risk. Monitor
WARFARIN SODIUM
Theoretical potential for MELOXICAM [RECTUM] reducing the ANTICOAGULANT effect of WARFARIN SODIUM. Moderate risk. Monitor
ZAFIRLUKAST
Infrequent reports of MELOXICAM [RECTUM] reducing the BRONCHODILATOR effect of ZAFIRLUKAST. Moderate risk. Avoid